急騰。11日の取引終了後に24年10月期の業績を発表し、好材料視されている。24年10月期の売上高は12.18億円(前年同期比+36.3%)、営業利益は2.50億円(同+53.9%)、経常利益は2.51億円(同+54.2%)と大幅増収増益となった。契約件数等が堅調に推移し、売上は順調に推移した。25年10月期も大幅増収増益を見込み、過去最高益を更新する見通しとなっている。＜4599＞ Stem Inc 324 -19
Continuing to decline. Announced the performance for the first quarter of the fiscal year ending July 25, with no business revenue (no business revenue in the same period last year), an operating loss of 0.573 billion yen (operating loss of 0.491 billion yen in the same period), an ordinary loss of 0.573 billion yen (ordinary loss of 0.491 billion yen in the same period), and a quarterly net loss of 0.56 billion yen (quarterly net loss of 0.467 billion yen in the same period), which has caused concern due to the widening loss. The company's business revenue largely depends on milestone revenue associated with development progress and is greatly influenced by the development strategy and schedule of partners, which may lead to significant volatility in business revenue amounts each fiscal year.
＜5132＞ pluszero 2606 +333
Soaring. They announced their performance for the fiscal year ending October 24 after the trading concluded on the 11th and are viewed positively. In the fiscal year ending October 24, revenue was 1.218 billion yen (up 36.3% year-on-year), operating profit was 0.25 billion yen (up 53.9%), and ordinary profit was 0.251 billion yen (up 54.2%), achieving significant increases in both revenue and profit. The number of contracts and other metrics steadily progressed, and sales were smoothly trending. A substantial increase in revenue and profit is also expected for the fiscal year ending October 25, and a record profit is anticipated.
＜4583＞ Kaiomu 228 +27
Significant rebound. Announced that they have concluded a joint research agreement with Eisai to create high-affinity antibodies using their original antibody discovery technology, the ADLib system, which is viewed positively. Antibody engineering is the process of enhancing the functions of isolated antibodies in line with specific objectives and is a highly important technology in the antibody production process. The ADLib system not only acquires antibodies against targets but has also demonstrated the high-functionality of antibodies utilizing the property of accumulating mutations in antibody genes in previous research.
＜4263＞ Sasmid 585 -5
Buying leading but gradually losing value and in a sideways move. Completed the construction of an integrated venous disease registry system based on the basic agreement concluded with Tohoku Universities, and began providing it to companies. This registry can simultaneously collect information from patients using multiple Medical Devices, including a new venous stent for symptomatic iliac-femoral vein outflow obstruction and a new thrombectomy catheter for acute deep vein thrombosis. By sharing the collected data with related academic societies and manufacturers, it will be used in the development of appropriate use guidelines issued by related academic societies and in post-marketing studies, among other uses.
＜186A＞ Astroscale 830 +2
Consolidation. Subsidiary Astroscale announced that it successfully approached to within about 15 meters of target debris in the commercial debris removal demonstration satellite "ADRAS-J" mission, which started in February. This approach was carried out independently by the operator outside the mission requirements of the Japan Aerospace Exploration Agency (JAXA), marking the closest distance ever achieved to actual debris by a private company through RPO (Rendezvous and Proximity Operations). However, caution regarding tomorrow's Earnings Reports led to buying ahead, followed by continued consolidation.
＜3491＞ GA TECH 1212 -53
Reversal. Announced financial results for the fiscal year ending October 2024. Revenue totaled 189.883 billion yen (up 29.5% year-on-year), operating profit was 4.056 billion yen (up 86.6% year-on-year), and net income attributable to shareholders of the parent company was 1.841 billion yen (up 82.2% year-on-year), showing significant growth in both revenue and profit. The flow business aims to expand operations through improved fees and an expanded product lineup, and has shifted to a solid revenue structure through the accumulation of stable revenue in the stock business, and expects double-digit growth in both revenue and profit for the fiscal year ending October 2025. However, the initial buying was also held back by selling pressure, resulting in a reversal.
